Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?

[1]  K. Rahbar,et al.  PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  M. Zou,et al.  Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of 68Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer , 2020, Abdominal Radiology.

[3]  O. Sanli,et al.  Detection of metastases in newly diagnosed prostate cancer by using 68Ga-PSMA PET/CT and its relationship with modified D’Amico risk classification , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  E. Goetghebeur,et al.  Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial. , 2020 .

[5]  P. Dahm,et al.  Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer: a Cochrane Review , 2019, BJU international.

[6]  E. Demirci,et al.  Clinical Impact of Lower-Limb Imaging in 68Ga-PSMA PET/CT for Patients with Prostate Cancer , 2019, The Journal of Nuclear Medicine Technology.

[7]  N. Clarke,et al.  Primary Mutational Landscape Linked with Pre-Docetaxel Lactate Dehydrogenase Levels Predicts Docetaxel Response in Metastatic Castrate-Resistant Prostate Cancer. , 2019, European urology focus.

[8]  M. Uder,et al.  68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients , 2019, Annals of Nuclear Medicine.

[9]  Prashanth Rawla,et al.  Epidemiology of Prostate Cancer , 2019, World journal of oncology.

[10]  M. Parmar,et al.  Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial , 2018, The Lancet.

[11]  Steven P. Rowe,et al.  Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications , 2018, Annals of Nuclear Medicine.

[12]  Chong Hyun Suh,et al.  Impact of 68Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis. , 2018, European urology.

[13]  O. Sanli,et al.  Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer , 2017, Annals of Nuclear Medicine.

[14]  Steven P Rowe,et al.  Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen–Targeted PET Imaging: PSMA-RADS Version 1.0 , 2017, The Journal of Nuclear Medicine.

[15]  Markus Krönke,et al.  Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumor Burden in Prostate Cancer Using 68Ga-PSMA PET/CT , 2017, The Journal of Nuclear Medicine.

[16]  Tobias L. Ross,et al.  Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[17]  Matthew R. Cooperberg,et al.  Epidemiology of prostate cancer , 2017, World Journal of Urology.

[18]  R. DiPaola,et al.  Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial , 2016 .

[19]  Susan Halabi,et al.  Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Oliver Sartor,et al.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Schwaiger,et al.  Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  M. Schwaiger,et al.  Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  M. Schwaiger,et al.  Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy , 2016, The Journal of Nuclear Medicine.

[24]  A. Ravaud,et al.  Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. , 2015, European urology.

[25]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[26]  E. Francini,et al.  PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials , 2014, Tumor Biology.

[27]  M. Rubin,et al.  Aggressive Variants of Castration-Resistant Prostate Cancer , 2014, Clinical Cancer Research.

[28]  J. Epstein,et al.  Small cell carcinoma of the prostate , 2014, Nature Reviews Urology.

[29]  A. Armstrong,et al.  Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. , 2013, Journal of the National Cancer Institute.

[30]  O. Ratib,et al.  Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases , 2013, Acta oncologica.

[31]  I. Tannock,et al.  Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer , 2009, Clinical Cancer Research.

[32]  I. Tannock,et al.  A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis , 2007, Clinical Cancer Research.

[33]  F. Saad,et al.  Markers of Bone Metabolism and Survival in Men with Hormone-Refractory Metastatic Prostate Cancer , 2006, Clinical Cancer Research.

[34]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[35]  W. Gerald,et al.  Gene expression profiling predicts clinical outcome of prostate cancer. , 2004, The Journal of clinical investigation.

[36]  H. Moch,et al.  Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. , 2000, Human pathology.

[37]  D. Bostwick,et al.  Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. , 1998, Urology.

[38]  F. Johnson,et al.  Small cell carcinoma of the prostate , 1991, Cancer.

[39]  I. Tannock,et al.  The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. , 2014, European urology.